An important call: Suggestion of using IL-10 as therapeutic agent for COVID-19 with ARDS and other complications

References

• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–14. DOI:10.1016/s0140-6736(20)30183-5
   PubMed Web of Science ®Google Scholar
• Wilder-Smith A, Chiew CJ, Lee VJ. Can we contain the COVID-19 outbreak with the same measures as for SARS? Lancet Infect Dis. 2020;20(5):e102–107.
   PubMed Web of Science ®Google Scholar
• Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–1034.
   PubMed Web of Science ®Google Scholar
• Rahmati M. Cytokine-targeted therapy in severely ill COVID-19 patients: options and cautions. Eurasian J Med Oncol. 2020. DOI:10.14744/ejmo.2020.72142
   PubMedGoogle Scholar
• Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J. 2020;55(4):2000607.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Xu J, Zhou C, et al. Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome. Am J Respir Crit Care Med. 2005;171(8):850–857.
   PubMed Web of Science ®Google Scholar
• Rockx B, Baas T, Zornetzer GA, et al. Early upregulation of acute respiratory distress syndrome-associated cytokines promotes lethal disease in an aged-mouse model of severe acute respiratory syndrome coronavirus infection. J Virol. 2009;83(14):7062–7074. DOI:10.1128/JVI.00127-09
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li J, Zhan Y, et al. Analysis of serum cytokines in patients with severe acute respiratory syndrome. Infect Immun. 2004;72(8):4410–4415. DOI:10.1128/IAI.72.8.4410-4415.2004
   PubMed Web of Science ®Google Scholar
• Hensley LE, Fritz LE, Jahrling PB, et al. Interferon-β 1a and SARS Coronavirus replication. Emerg Infect Dis. 2004;10(2):317–319.
   PubMed Web of Science ®Google Scholar
• Hu W, Yen YT, Singh S, et al. SARS-Cov regulates immune function-related gene expression in human monocytic cells. Viral Immunol. 2012;25(4):277–288.
   PubMed Web of Science ®Google Scholar
• Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529–539.
   PubMed Web of Science ®Google Scholar
• Chien JY, Hsueh PR, Cheng WC, et al. Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome. Respirology. 2006;11(6):715–722.
   PubMed Web of Science ®Google Scholar
• Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. Virol Sin. 2020;35(3):266–271.
   PubMed Web of Science ®Google Scholar
• Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York city: prospective cohort study. BMJ. 2020;369:m1966.
   PubMed Web of Science ®Google Scholar
• Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–Infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069. DOI:10.1001/jama.2020.1585
   PubMed Web of Science ®Google Scholar
• Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA. 2020;323(20):2052–2059. DOI:10.1001/jama.2020.6775
   PubMed Web of Science ®Google Scholar
• Tsou A, Chen PJ, Tsai KW, et al. THαβ immunological pathway as protective immune response against prion diseases: an insight for prion infection therapy. Viruses. 2022;14(2):408.
   PubMed Web of Science ®Google Scholar
• Hu WC. Human immune responses to Plasmodium falciparum infection: molecular evidence for a suboptimal THαβ and TH17 bias over ideal and effective traditional TH1 immune response. Malar J. 2013;12(1):392.
   PubMedGoogle Scholar
• Kong SL, Chui P, Lim B, et al. Elucidating the molecular physiopathology of acute respiratory distress syndrome in severe acute respiratory syndrome patients. Virus Res. 2009;145(2):260–269.
   PubMed Web of Science ®Google Scholar
• Lee EJ, Lim JY, Lee SY, et al. The expression of HSPs, anti-oxidants, and cytokines in plasma and bronchoalveolar lavage fluid of patients with acute respiratory distress syndrome. Clin Biochem. 2012;45(6):493–498.
   PubMed Web of Science ®Google Scholar
• Papadakos PJ. Cytokines, genes, and ARDS. Chest. 2002;121(5):1391–1392.
   PubMed Web of Science ®Google Scholar
• Downey GP, Dong Q, Kruger J, et al. Regulation of neutrophil activation in acute lung injury. Chest. 1999;116:46S–54S.
   PubMed Web of Science ®Google Scholar
• Lee WL, Downey GP. Neutrophil activation and acute lung injury. Curr Opin Crit Care. 2001;7(1):1–7.
   PubMedGoogle Scholar
• Charles PE, Tissieres P, Barbar SD, et al. Mild-stretch mechanical ventilation upregulates toll-like receptor 2 and sensitizes the lung to bacterial lipopeptide. crit care. 2011;15(4):R181.
   PubMed Web of Science ®Google Scholar
• Fan J, Li Y, Vodovotz Y, et al. Hemorrhagic shock-activated neutrophils augment TLR4 signaling-induced TLR2 upregulation in alveolar macrophages: role in hemorrhage-primed lung inflammation. Am J Physiol Lung Cell Mol Physiol. 2006;290(4):L738–746.
   PubMed Web of Science ®Google Scholar
• Imai Y, Kuba K, Neely GG, et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell. 2008;133(2):235–249. DOI:10.1016/j.cell.2008.02.043
   PubMed Web of Science ®Google Scholar
• Jiang D, Liang J, Fan J, et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med. 2005;11(11):1173–1179. DOI:10.1038/nm1315
   PubMed Web of Science ®Google Scholar
• Lv T, Shen X, Shi Y, et al. TLR4 is essential in acute lung injury induced by unresuscitated hemorrhagic shock. J Trauma. 2009;66(1):124–131.
   PubMedGoogle Scholar
• Sharif R, Dawra R, Wasiluk K, et al. Impact of toll-like receptor 4 on the severity of acute pancreatitis and pancreatitis-associated lung injury in mice. Gut. 2009;58(6):813–819.
   PubMed Web of Science ®Google Scholar
• Togbe D, Schnyder-Candrian S, Schnyder B, et al. TLR4 gene dosage contributes to endotoxin-induced acute respiratory inflammation. J Leukocyte Biol. 2006;80(3):451–457.
   PubMed Web of Science ®Google Scholar
• Wu TT, Chen TL, Loon WS, et al. Lipopolysaccharide stimulates syntheses of toll-like receptor 2 and surfactant protein-A in human alveolar epithelial A549 cells through upregulating phosphorylation of MEK1 and ERK1/2 and sequential activation of NF-κB. Cytokine. 2011;55(1):40–47.
   PubMed Web of Science ®Google Scholar
• Reino DC, Pisarenko V, Palange D, et al. Trauma hemorrhagic shock-induced lung injury involves a gut-lymph-induced TLR4 pathway in mice. PLoS ONE. 2011;6(8):e14829. DOI:10.1371/journal.pone.0014829
   PubMed Web of Science ®Google Scholar
• Chase MA, Wheeler DS, Lierl KM, et al. Hsp72 induces inflammation and regulates cytokine production in airway epithelium through a TLR4- and NF-κB-Dependent mechanism. J Immunol. 2007;179(9):6318–6324.
   PubMed Web of Science ®Google Scholar
• Ganter MT, Ware LB, Howard M, et al. Extracellular heat shock protein 72 is a marker of the stress protein response in acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2006;291(3):L354–361.
   PubMed Web of Science ®Google Scholar
• Krzyzaniak M, Cheadle G, Peterson C, et al. Burn-induced acute lung injury requires a functional Toll-like receptor 4. Shock. 2011;36(1):24–29.
   PubMed Web of Science ®Google Scholar
• Khair OA, Davies RJ, Devalia JL. Bacterial-induced release of inflammatory mediators by bronchial epithelial cells. Eur Respir J. 1996;9(9):1913–1922.
   PubMed Web of Science ®Google Scholar
• Smart SJ, Casale TB. Pulmonary epithelial cells facilitate TNF-alpha-induced neutrophil chemotaxis. A role for cytokine networking. J Immunol. 1994;152(8):4087–4094.
   PubMed Web of Science ®Google Scholar
• Thorley AJ, Ford PA, Giembycz MA, et al. Differential regulation of cytokine release and leukocyte migration by lipopolysaccharide-stimulated primary human lung alveolar type II epithelial cells and macrophages. J Immunol. 2007;178(1):463–473.
   PubMed Web of Science ®Google Scholar
• Kurdowska A, Miller EJ, Noble JM, et al. Anti-IL-8 autoantibodies in alveolar fluid from patients with the adult respiratory distress syndrome. J Immunol. 1996;157(6):2699–2706.
   PubMed Web of Science ®Google Scholar
• Kunkel SL, Standiford T, Kasahara K, et al. Interleukin-8 (IL-8): the major neutrophil chemotactic factor in the lung. Exp Lung Res. 1991;17(1):17–23.
   PubMed Web of Science ®Google Scholar
• Lin G, Pearson AE, Scamurra RW, et al. Regulation of interleukin-8 expression in porcine alveolar macrophages by bacterial lipopolysaccharide. J Biol Chem. 1994;269(1):77–85.
   PubMed Web of Science ®Google Scholar
• Nakamura H, Yoshimura K, Jaffe HA, et al. Interleukin-8 gene expression in human bronchial epithelial cells. J Biol Chem. 1991;266(29):19611–19617.
   PubMed Web of Science ®Google Scholar
• Standiford TJ, Kunkel SL, Basha MA, et al. Interleukin-8 gene expression by a pulmonary epithelial cell line. A model for cytokine networks in the lung. J Clin Invest. 1990;86(6):1945–1953.
   PubMed Web of Science ®Google Scholar
• Strieter RM, Chensue SW, Basha MA, et al. Human alveolar macrophage gene expression of interleukin-8 by tumor necrosis factor- α , lipopolysaccharide, and interleukin-1 β. Am J Respir Cell Mol Biol. 1990;2(4):321–326.
   PubMed Web of Science ®Google Scholar
• De Luca D, Minucci A, Cogo P, et al. Secretory phospholipase a pathway during pediatric acute respiratory distress syndrome: a preliminary study. Pediatr Crit Care Med. 2011;12(1):e20–24.
   PubMed Web of Science ®Google Scholar
• Donnelly SC, Kunkel RM, Strieter SL, et al. Interleukin-8 and development of adult respiratory distress syndrome in at-risk patient groups. Lancet. 1993;341(8846):643–647.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Miyasaka H, Ota H, et al. Purification and partial primary sequence of a chemotactic protein for polymorphonuclear leukocytes derived from human lung giant cell carcinoma LU65C cells. J Exp Med. 1989;169(6):1895–1901.
   PubMed Web of Science ®Google Scholar
• Frevert CW, Goodman RB, Kinsella MG, et al. Tissue-specific mechanisms control the retention of IL-8 in lungs and skin. J Immunol. 2002;168(7):3550–3556.
   PubMed Web of Science ®Google Scholar
• Frevert CW, Kinsella MG, Vathanaprida C, et al. Binding of interleukin-8 to heparan sulfate and chondroitin sulfate in lung tissue. Am J Respir Cell Mol Biol. 2003;28(4):464–472.
   PubMed Web of Science ®Google Scholar
• Fahy RJ, Lichtenberger F, McKeegan CB, et al. The acute respiratory distress syndrome: a role for transforming growth factor-beta 1. Am J Respir Cell Mol Biol. 2003;28(4):499–503.
   PubMed Web of Science ®Google Scholar
• Takatsuka H, Takemoto Y, Mori A, et al. Common features in the onset of ARDS after administration of granulocyte colony-stimulating factor. Chest. 2002;121(5):1716–1720.
   PubMed Web of Science ®Google Scholar
• Tanaka S, Nishiumi S, Nishida M, et al. Vitamin K3 attenuates lipopolysaccharide-induced acute lung injury through inhibition of nuclear factor-κB activation. Clin Exp Immunol. 2010;160(2):283–292. DOI:10.1111/j.1365-2249.2009.04083.x
   PubMed Web of Science ®Google Scholar
• von Bismarck P, Klemm K, Garcia Wistadt CF, et al. Selective NF-κB inhibition, but not dexamethasone, decreases acute lung injury in a newborn piglet airway inflammation model. Pulm Pharmacol Ther. 2009;22(4):297–304.
   PubMed Web of Science ®Google Scholar
• Wu CL, Lin LY, Yang JS, et al. Attenuation of lipopolysaccharide-induced acute lung injury by treatment with IL-10. Respirology. 2009;14(4):511–521.
   PubMed Web of Science ®Google Scholar
• Van den Steen PE, Geurts N, Deroost K, et al. Immunopathology and dexamethasone therapy in a new model for malaria-associated acute respiratory distress syndrome. Am J Respir Crit Care Med. 2010;181(9):957–968.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Sun H, Fan L, et al. Acute respiratory distress syndrome induced by a swine 2009 H1N1 variant in mice. PLoS ONE. 2012;7:e29347.
   PubMed Web of Science ®Google Scholar
• Daniels CE, Wilkes MC, Edens M, et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-β and prevents bleomycin-mediated lung fibrosis. J Clin Invest. 2004;114(9):1308–1316.
   PubMed Web of Science ®Google Scholar
• Border WA, Noble NA, Noble NA. Transforming growth factor β in tissue fibrosis. N Engl J Med. 1994;331(19):1286–1292.
   PubMed Web of Science ®Google Scholar
• Kitamura H, Cambier S, Somanath S, et al. Mouse and human lung fibroblasts regulate dendritic cell trafficking, airway inflammation, and fibrosis through integrin αvβ8–mediated activation of TGF-β. J Clin Invest. 2011;121(7):2863–2875. DOI:10.1172/jci45589
   PubMed Web of Science ®Google Scholar
• Yang HZ, Wang JP, Mi S, et al. TLR4 activity is required in the resolution of pulmonary inflammation and fibrosis after acute and chronic lung injury. Am J Pathol. 2012;180(1):275–292. DOI:10.1016/j.ajpath.2011.09.019
   PubMed Web of Science ®Google Scholar
• Hagiwara S, Iwasaka H, Matsumoto S, et al. Association between heat stress protein 70 induction and decreased pulmonary fibrosis in an animal model of acute lung injury. Lung. 2007;185(5):287–293.
   PubMed Web of Science ®Google Scholar
• Hilberath JN, Carlo T, Pfeffer MA, et al. Resolution of Toll-like receptor 4-mediated acute lung injury is linked to eicosanoids and suppressor of cytokine signaling 3. Faseb J. 2011;25(6):1827–1835.
   PubMed Web of Science ®Google Scholar
• Sakashita A, Nishimura Y, Nishiuma T, et al. Neutrophil elastase inhibitor (sivelestat) attenuates subsequent ventilator-induced lung injury in mice. Eur J Pharmacol. 2007;571(1):62–71.
   PubMed Web of Science ®Google Scholar
• Herold S, Becker C, Ridge KM, et al. Influenza virus-induced lung injury: pathogenesis and implications for treatment. Eur Respir J. 2015;45(5):1463–1478.
   PubMed Web of Science ®Google Scholar
• Luyt C, Combes A, Trouillet JL, et al. Virus-induced acute respiratory distress syndrome: epidemiology, management and outcome. La Presse Médicale. 2011;40(12):e561–568.
   PubMedGoogle Scholar
• Wu Z, Zhang R, Liu D, et al. Acute respiratory distress syndrome caused by human adenovirus in adults: a prospective observational study in Guangdong, China. Front Med (Lausanne). 2021;8:791163.
   PubMed Web of Science ®Google Scholar
• Aslan A, Aslan C, Zolbanin NM, et al. Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management. Pneumonia. 2021;13(1):14.
   Web of Science ®Google Scholar
• Quan C, Li C, Ma H, et al. Immunopathogenesis of coronavirus-induced Acute Respiratory Distress Syndrome (ARDS): potential infection-associated hemophagocytic lymphohistiocytosis. Clinical Microbiology Reviews. 2020;34(1). DOI:10.1128/cmr.00074-20
   PubMed Web of Science ®Google Scholar
• Selvaraj V, Finn A, Lal A, et al. Baricitinib in hospitalised patients with COVID-19: a meta-analysis of randomised controlled trials. EClinicalMedicine. 2022;49:101489.
   PubMedGoogle Scholar
• Spinelli FR, Conti F, Gadina M. HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19. Sci Immunol. 2020;5(47). DOI:10.1126/sciimmunol.abc5367
   PubMed Web of Science ®Google Scholar
• Wang CJ, Truong AK. COVID-19 infection on IL-23 inhibition. Dermatologic Therapy. 2020;33(6):e13893.
   PubMed Web of Science ®Google Scholar
• Zou Y, Meng Z. Literature overview of the IL-17 inhibition from psoriasis to COVID-19. J Inflamm Res. 2021;14:5611–5618.
   PubMed Web of Science ®Google Scholar
• Naing A, Wong DJ, Infante JR, et al. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. Lancet Oncol. 2019;20(11):1544–1555. DOI:10.1016/s1470-2045(19)30514-5
   PubMed Web of Science ®Google Scholar
• Rojas JM, Avia M, Martin V, et al. IL-10: a multifunctional cytokine in viral infections. J Immunol Res. 2017;2017:6104054.
   PubMed Web of Science ®Google Scholar
• Cinatl J, Morgenstern B, Bauer G, et al. Treatment of SARS with human interferons. Lancet. 2003;362(9380):293–294.
   PubMed Web of Science ®Google Scholar
• Dandekar S, Perlman AA. Immunopathogenesis of coronavirus infections: implications for SARS. Nat Rev Immunol. 2005;5(12):917–927.
   PubMed Web of Science ®Google Scholar
• Cush SS, Reynoso GV, Kamenyeva O, et al. Locally produced IL-10 limits cutaneous vaccinia virus spread. PLOS Pathog. 2016;12(3):e1005493.
   PubMed Web of Science ®Google Scholar
• Jiang L, Yao S, Huang S, et al. Type I IFN signaling facilitates the development of IL-10-producing effector CD8 + T cells during murine influenza virus infection. Eur J Immunol. 2016;46(12):2778–2788.
   PubMed Web of Science ®Google Scholar
• Loebbermann J, Schnoeller C, Thornton H, et al. IL-10 regulates viral lung immunopathology during acute respiratory syncytial virus infection in mice. PLoS ONE. 2012;7(2):e32371.
   PubMed Web of Science ®Google Scholar
• Naicker DD, Werner L, Kormuth E, et al. Interleukin-10 promoter polymorphisms influence HIV-1 susceptibility and primary HIV-1 pathogenesis. J Infect Dis. 2009;200(3):448–452.
   PubMed Web of Science ®Google Scholar
• Savarin C, Bergmann CC. Fine tuning the cytokine storm by IFN and IL-10 following neurotropic coronavirus encephalomyelitis. Front Immunol. 2018;9:3022.
   PubMed Web of Science ®Google Scholar
• Sun J, Madan R, Karp CL, et al. Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10. Nat Med. 2009;15(3):277–284.
   PubMed Web of Science ®Google Scholar
• Sun K, Torres L, Metzger DW. A detrimental effect of interleukin-10 on protective pulmonary humoral immunity during primary influenza a virus infection. J Virol. 2010;84(10):5007–5014.
   PubMed Web of Science ®Google Scholar
• Swarup V, Ghosh J, Duseja R, et al. Japanese encephalitis virus infection decrease endogenous IL-10 production: correlation with microglial activation and neuronal death. Neurosci Lett. 2007;420(2):144–149.
   PubMed Web of Science ®Google Scholar
• Tian Y, Seumois G, De-Oliveira-Pinto LM, et al. Molecular signatures of dengue virus-specific IL-10/ifn-γ co-producing CD4 T cells and their association with dengue disease. Cell Rep. 2019;29(13):4482–4495 e4484. DOI:10.1016/j.celrep.2019.11.098
   PubMed Web of Science ®Google Scholar
• Tumpey TM, Elner VM, Chen SH, et al. Interleukin-10 treatment can suppress stromal keratitis induced by herpes simplex virus type 1. J Immunol. 1994;153(5):2258–2265.
   PubMed Web of Science ®Google Scholar
• Wang Y, Rice AP. Interleukin-10 inhibits HIV-1 LTR-directed gene expression in human macrophages through the induction of cyclin T1 proteolysis. Virology. 2006;352(2):485–492.
   PubMed Web of Science ®Google Scholar
• Perlman S, Zhao J. Roles of regulatory T cells and IL-10 in virus-induced demyelination. J Neuroimmunol. 2017;308:6–11.
   PubMed Web of Science ®Google Scholar
• Puntambekar SS, Hinton DR, Yin X, et al. Interleukin-10 is a critical regulator of white matter lesion containment following viral induced demyelination. Glia. 2015;63(11):2106–2120.
   PubMed Web of Science ®Google Scholar
• Trandem K, Jin Q, Weiss KA, et al. Virally expressed interleukin-10 ameliorates acute encephalomyelitis and chronic demyelination in coronavirus-infected mice. J Virol. 2011;85(14):6822–6831.
   PubMed Web of Science ®Google Scholar
• Trandem K, Zhao J, Fleming E, et al. Highly activated cytotoxic CD8 T cells express protective IL-10 at the peak of coronavirus-induced encephalitis. J Immunol. 2011;186(6):3642–3652.
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhao J, Fett C, et al. IFN-γ– and IL-10–expressing virus epitope-specific Foxp3+ T reg cells in the central nervous system during encephalomyelitis. J Exp Med. 2011;208(8):1571–1577.
   PubMed Web of Science ®Google Scholar
• Liu Y, de Waal Malefyt R, Briere F, et al. The EBV IL-10 homologue is a selective agonist with impaired binding to the IL-10 receptor. J Immunol. 1997;158(2):604–613.
   PubMed Web of Science ®Google Scholar
• Ouyang P, Rakus K, van Beurden SJ, et al. IL-10 encoded by viruses: a remarkable example of independent acquisition of a cellular gene by viruses and its subsequent evolution in the viral genome. J Gen Virol. 2014;95(2):245–262.
   PubMedGoogle Scholar
• Avdic S, McSharry BP, Slobedman B. Modulation of dendritic cell functions by viral IL-10 encoded by human cytomegalovirus. Front Microbiol. 2014;5:337.
   PubMed Web of Science ®Google Scholar
• Kotenko SV, Saccani S, Izotova LS, et al. Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). Proc Natl Acad Sci U S A. 2000;97(4):1695–1700.
   PubMed Web of Science ®Google Scholar
• Slobedman B, Barry PA, Spencer JV, et al. Virus-encoded homologs of cellular interleukin-10 and their control of host immune function. J Virol. 2009;83(19):9618–9629.
   PubMed Web of Science ®Google Scholar
• Spencer JV, Lockridge KM, Barry PA, et al. Potent immunosuppressive activities of cytomegalovirus-encoded interleukin-10. J Virol. 2002;76(3):1285–1292.
   PubMed Web of Science ®Google Scholar
• Chang WL, Barry PA, Szubin R, et al. Human cytomegalovirus suppresses type I interferon secretion by plasmacytoid dendritic cells through its interleukin 10 homolog. Virology. 2009;390(2):330–337.
   PubMed Web of Science ®Google Scholar
• Chang WL, Baumgarth N, Yu D, et al. Human cytomegalovirus-encoded interleukin-10 homolog inhibits maturation of dendritic cells and alters their functionality. J Virol. 2004;78(16):8720–8731.
   PubMed Web of Science ®Google Scholar
• Mocellin S, Panelli MC, Wang E, et al. The dual role of IL-10. Trends Immunol. 2003;24(1):36–43.
   PubMed Web of Science ®Google Scholar
• Zheng LM, Ojcius DM, Garaud F, et al. Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J Exp Med. 1996;184(2):579–584. DOI:10.1084/jem.184.2.579
   PubMed Web of Science ®Google Scholar
• Malisan F, Brière F, Bridon JM, et al. Interleukin-10 induces immunoglobulin G isotype switch recombination in human CD40-activated naive B lymphocytes. J Exp Med. 1996;183(3):937–947.
   PubMed Web of Science ®Google Scholar
• Fujii S, Shimizu K, Shimizu T, et al. Interleukin-10 promotes the maintenance of antitumor CD8(+) T-cell effector function in situ. Blood. 2001;98(7):2143–2151.
   PubMed Web of Science ®Google Scholar
• Hu WC. A framework of all discovered immunological pathways and their roles for four specific types of pathogens and hypersensitivities. Front Immunol. 2020;11:1992.
   PubMed Web of Science ®Google Scholar
• Blackburn SD, Wherry EJ. IL-10, T cell exhaustion and viral persistence. Trends Microbiol. 2007;15(4):143–146.
   PubMed Web of Science ®Google Scholar
• Brooks DG, Trifilo MJ, Edelmann KH, et al. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med. 2006;12(11):1301–1309.
   PubMed Web of Science ®Google Scholar
• Tinoco R, Alcalde V, Yang Y, et al. Cell-intrinsic transforming growth factor-β signaling mediates virus-specific CD8+ T cell deletion and viral persistence in vivo. Immunity. 2009;31(1):145–157.
   PubMed Web of Science ®Google Scholar
• Murray PJ. The primary mechanism of the IL-10-regulated antiinflammatory response is to selectively inhibit transcription. Proc Natl Acad Sci U S A. 2005;102(24):8686–8691.
   PubMed Web of Science ®Google Scholar
• Hutchins AP, Diez D, Miranda-Saavedra D. The IL-10/stat3-mediated anti-inflammatory response: recent developments and future challenges. Brief Funct Genomics. 2013;12(6):489–498.
   PubMed Web of Science ®Google Scholar
• Kessler B, Rinchai D, Kewcharoenwong C, et al. Interleukin 10 inhibits pro-inflammatory cytokine responses and killing of Burkholderia pseudomallei. Sci Rep. 2017;7(1):42791.
   PubMedGoogle Scholar
• Krause P, Morris V, Greenbaum JA, et al. IL-10-producing intestinal macrophages prevent excessive antibacterial innate immunity by limiting IL-23 synthesis. Nat Commun. 2015;6(1):7055. DOI:10.1038/ncomms8055
   PubMedGoogle Scholar
• Shouval DS, Biswas A, Goettel JA, et al. Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and anti-inflammatory macrophage function. Immunity. 2014;40(5):706–719. DOI:10.1016/j.immuni.2014.03.011
   PubMed Web of Science ®Google Scholar
• Dang PM, Elbim C, Marie JC, et al. Anti-inflammatory effect of interleukin-10 on human neutrophil respiratory burst involves inhibition of GM-CSF-induced p47phox phosphorylation through a decrease in ERK1/2 activity. Faseb J. 2006;20(9):1504–1506.
   PubMed Web of Science ®Google Scholar
• Laichalk LL, Danforth JM, Standiford TJ. Interleukin-10 inhibits neutrophil phagocytic and bactericidal activity. FEMS Immunol Med Microbiol. 1996;15(4):181–187.
   PubMedGoogle Scholar
• Gu Y, Yang J, Ouyang X, et al. Interleukin 10 suppresses Th17 cytokines secreted by macrophages and T cells. Eur J Immunol. 2008;38(7):1807–1813. DOI:10.1002/eji.200838331
   PubMed Web of Science ®Google Scholar
• Guo B. IL-10 modulates TH17 pathogenicity during autoimmune diseases. J Clin Cell Immunol. 2016;7(02). DOI:10.4172/2155-9899.1000400
   Google Scholar
• Kulcsar KA, Baxter VK, Greene IP, et al. Interleukin 10 modulation of pathogenic Th17 cells during fatal alphavirus encephalomyelitis. Proc Natl Acad Sci U S A. 2014;111(45):16053–16058.
   PubMed Web of Science ®Google Scholar
• Li B, Gurung P, Malireddi RK, et al. IL-10 engages macrophages to shift Th17 cytokine dependency and pathogenicity during T-cell-mediated colitis. Nat Commun. 2015;6(1):6131.
   PubMedGoogle Scholar
• Liu B, Tonkonogy SL, Sartor RB. Antigen-presenting cell production of IL-10 inhibits T-helper 1 and 17 cell responses and suppresses colitis in mice. Gastroenterology. 2011;141(2):653–662. 10.1053/j.gastro.2011.04.053. 662 e651-654.
   PubMed Web of Science ®Google Scholar
• Xu S, Xu M, Li GG, et al. Early recruitment of IL-10-producing B cells into alveoli improved the resolution of acute lung injury. Cell Physiol Biochem. 2016;38(5):1752–1760.
   PubMedGoogle Scholar
• Kapur R, Kim M, Rebetz J, et al. Low levels of interleukin-10 in patients with transfusion-related acute lung injury. Ann Transl Med. 2017;5(16):339.
   PubMed Web of Science ®Google Scholar
• Kapur R, Kim M, Aslam R, et al. T regulatory cells and dendritic cells protect against transfusion-related acute lung injury via IL-10. Blood. 2017;129(18):2557–2569. DOI:10.1182/blood-2016-12-758185
   PubMed Web of Science ®Google Scholar
• Garantziotis S, Brass DM, Savov J, et al. Leukocyte-derived IL-10 reduces subepithelial fibrosis associated with chronically inhaled endotoxin. Am J Respir Cell Mol Biol. 2006;35(6):662–667.
   PubMed Web of Science ®Google Scholar
• Shi J, Li J, Guan H, et al. Anti-fibrotic actions of interleukin-10 against hypertrophic scarring by activation of PI3K/AKT and STAT3 signaling pathways in scar-forming fibroblasts. PLoS ONE. 2014;9(5):e98228. DOI:10.1371/journal.pone.0098228
   PubMed Web of Science ®Google Scholar
• Ito T, Okada T, Miyashita H, et al. Interleukin-10 expression mediated by an adeno-associated virus vector prevents monocrotaline-induced pulmonary arterial hypertension in rats. Circ Res. 2007;101(7):734–741. DOI:10.1161/CIRCRESAHA.107.153023
   PubMed Web of Science ®Google Scholar
• Kurosaki F, Uchibori R, Sehara Y, et al. AAV6-mediated IL-10 expression in the lung ameliorates bleomycin-induced pulmonary fibrosis in mice. Hum Gene Ther. 2018;29(11):1242–1251.
   PubMed Web of Science ®Google Scholar
• Nakagome K, Dohi M, Okunishi K, et al. In vivo IL-10 gene delivery attenuates bleomycin induced pulmonary fibrosis by inhibiting the production and activation of TGF- in the lung. Thorax. 2006;61(10):886–894.
   PubMed Web of Science ®Google Scholar
• Spight D, Zhao B, Haas M, et al. Immunoregulatory effects of regulated, lung-targeted expression of IL-10 in vivo. Am J Physiol Lung Cell Mol Physiol. 2005;288(2):L251–265.
   PubMed Web of Science ®Google Scholar
• Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy—Review of a new approach. Pharmacol Rev. 2003;55(2):241–269.
   PubMed Web of Science ®Google Scholar
• Chernoff AE, Granowitz EV, Shapiro L, et al. A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J Immunol. 1995;154(10):5492–5499.
   PubMed Web of Science ®Google Scholar
• Huhn RD, Radwanski E, O’connell SM, et al. Pharmacokinetics and immunomodulatory properties of intravenously administered recombinant human interleukin-10 in healthy volunteers. Blood. 1996;87(2):699–705.
   PubMed Web of Science ®Google Scholar
• Mosser DM, Zhang X. Interleukin-10: new perspectives on an old cytokine. Immunol Rev. 2008;226(1):205–218.
   PubMed Web of Science ®Google Scholar
• Mattos A, de Jager-Krikken A, de Haan M, et al. Pegylation of interleukin-10 improves the pharmacokinetic profile and enhances the antifibrotic effectivity in CCl(4)-induced fibrogenesis in mice. J Control Release. 2012;162(1):84–91.
   PubMed Web of Science ®Google Scholar
• Barry JC, Shakibakho S, Durrer C, et al. Hyporesponsiveness to the anti-inflammatory action of interleukin-10 in type 2 diabetes. Sci Rep. 2016;6(1):21244.
   PubMedGoogle Scholar
• Yang L, Xie X, Tu Z, et al. The signal pathways and treatment of cytokine storm in COVID-19. Signal Transduct Target Ther. 2021;6(1):255.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Qin L, Zhang P, et al. Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease. JCI Insight. 2020;5(13).
   Web of Science ®Google Scholar
• Han H, Ma Q, Li C, et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect. 2020;9(1):1123–1130. DOI:10.1080/22221751.2020.1770129
   PubMed Web of Science ®Google Scholar
• Lu L, Zhang H, Dauphars DJ, et al. A potential role of interleukin 10 in COVID-19 pathogenesis. Trends Immunol. 2021;42(1):3–5.
   PubMed Web of Science ®Google Scholar
• Cheng L, Zhu Z, Wang C, et al. COVID-19 induces lower levels of IL-8, IL-10, and MCP-1 than other acute CRS-inducing diseases. Proc Natl Acad Sci U S A. 2021;118(21). DOI:10.1073/pnas.2102960118
   Web of Science ®Google Scholar
• Merza MY, Hwaiz RA, Hamad BK, et al. Analysis of cytokines in SARS-CoV-2 or COVID-19 patients in Erbil city, Kurdistan region of Iraq. PLoS ONE. 2021;16(4):e0250330.
   PubMed Web of Science ®Google Scholar
• Utrero-Rico A, Gonzalez-Cuadrado C, Chivite-Lacaba M, et al. Alterations in circulating monocytes predict COVID-19 severity and include chromatin modifications still detectable six months after recovery. Biomedicines. 2021;9(9):1253. DOI:10.3390/biomedicines9091253
   PubMed Web of Science ®Google Scholar
• McElvaney OJ, McEvoy NL, McElvaney OF, et al. Characterization of the inflammatory response to severe COVID-19 illness. Am J Respir Crit Care Med. 2020;202(6):812–821. DOI:10.1164/rccm.202005-1583OC
   PubMed Web of Science ®Google Scholar
• Sun J, Su J, Xie Y, et al. Plasma IL-6/IL-10 ratio and IL-8, LDH, and HBDH level predict the severity and the risk of death in AIDS patients with pneumocystis pneumonia. J Immunol Res. 2016;2016:1583951.
   PubMed Web of Science ®Google Scholar
• Taniguchi T, Koido Y, Aiboshi J, et al. Change in the ratio of interleukin-6 to interleukin-10 predicts a poor outcome in patients with systemic inflammatory response syndrome. Crit Care Med. 1999;27(7):1262–1264.
   PubMed Web of Science ®Google Scholar
• McElvaney OJ, Hobbs BD, Qiao D, et al. A linear prognostic score based on the ratio of interleukin-6 to interleukin-10 predicts outcomes in COVID-19. EBioMedicine. 2020;61:103026.
   PubMed Web of Science ®Google Scholar
• Malin JJ, Spinner CD, Janssens U, et al. Key summary of German national treatment guidance for hospitalized COVID-19 patients: key pharmacologic recommendations from a national German living guideline using an evidence to decision framework (last updated 17.05.2021). Infection. 2022;50(1):93–106. DOI:10.1007/s15010-021-01645-2
   PubMed Web of Science ®Google Scholar
• Sorgeloos F, Kreit M, Hermant P, et al. Antiviral type I and type III interferon responses in the central nervous system. Viruses. 2013;5(3):834–857.
   PubMed Web of Science ®Google Scholar
• Felgenhauer U, Schoen A, Gad HH, et al. Inhibition of SARS–CoV-2 by type I and type III interferons. J Biol Chem. 2020;295(41):13958–13964.
   PubMed Web of Science ®Google Scholar
• Zhang H, Madi A, Yosef N, et al. An IL-27-driven transcriptional network identifies regulators of IL-10 expression across T helper cell subsets. Cell Rep. 2020;33(8):108433. DOI:10.1016/j.celrep.2020.108433
   PubMed Web of Science ®Google Scholar
• Duan Y, Jia Y, Wang T, et al. Potent therapeutic target of inflammation, virus and tumor: focus on interleukin-27. Int Immunopharmacol. 2015;26(1):139–146.
   PubMed Web of Science ®Google Scholar
• Zhu H, Lou C, Liu P. Interleukin-27 ameliorates coxsackievirus-B3-induced viral myocarditis by inhibiting Th17 cells. Virol J. 2015;12(1):189.
   PubMedGoogle Scholar